We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Spruce Biosciences Inc (SPRB) USD0.0001

Sell:$0.40 Buy:$0.41 Change: $0.0154 (3.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.40
Buy:$0.41
Change: $0.0154 (3.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.40
Buy:$0.41
Change: $0.0154 (3.89%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare endocrine disorders with significant unmet medical needs. The Company is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). It is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). It has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. It has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The Company also investigates tildacerfont for the treatment of classic CAH in children.

Contact details

Address:
611 Gateway Boulevard, Suite 740
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (415) 6554168
Website:
https://sprucebio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SPRB
ISIN:
US85209E1091
Market cap:
$16.34 million
Shares in issue:
41.30 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Michael Grey
    Executive Chairman of the Board
  • Samir Gharib
    President, Chief Financial Officer
  • Javier Szwarcberg
    Chief Executive Officer, Director
  • Ralph Charlton
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.